The results of medical treatment of 93 patients with AP were studied: 82 — with the edematous form of AP, 11 — with pancreonecrosis. 39 patients have got a standard pathogenetic therapy, 54 were applied Octrestatin in complex medical treatment.
Incidence of pain syndrome, tachipnoe, tachicardy, absence of peristalsis, rate of elevated amilaza levels, diastase, lipase, trypsin, IL-1, rate of dysmicro-, macroelementoses for atomovits and toxic metals, incidence of enlarged pancreas, thermal flux density were lower in the Ocrestatin group. Application of Octrestatin in complex medical treatment of AP allowed to reduce the hospitalization term by 7.1 days. Lethality was 3.2 %.
Apllication of Octrestatin in a dose of 300–600 mg/days during 5–7 days in a complex medical treatment of acute pancreatitis is effective and pathogenetically grounded.